ASH Abstracts 2019

November 6, 2019

Oncopeptides to highlight data from melflufen clinical program in multiple myeloma and AL Amyloidosis in six presentations at ASH Annual Meeting 2019.

Abstracts

ANCHOR (OP-104) Updated Efficacy and Safety from a Phase 1 and 2 Study
pdf, 226 KB
Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multible Myeloma - HORIZON (OP-106)
pdf, 216 KB
In Vitro and in Vivo Activity of Melflufen in Amyloidosis
pdf, 129 KB
OP201 A Phase 12 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amy
pdf, 187 KB
The Burden of RelapsedRefractory Multiple Myeloma An Indirect Comparison of Health-Related Quality of Life
pdf, 272 KB
Updated Progression-Free Survival (PFS) and Overall Survival (OS) from phase 2 study O-12-M1
pdf, 343 KB